Urology
Volume 57, Issue 4, Supplement 1 , Pages 73-76 , April 2001

Proapoptotic anti-inflammatory drugs

  • Charles Myers

      Affiliations

    • University of Virginia Medical School, Charlottesville, Virginia, USA (CM)
    • Corresponding Author InformationReprint requests: Charles Myers, MD, University of Virginia Medical School, Box 334, Charlottesville, VA 22908
    • ,
  • Alane Koki

      Affiliations

    • Pharmacia Corporation, St. Louis, Missouri, USA (AK)
    • ,
  • Rifat Pamukcu

      Affiliations

    • Cell Pathways, Inc., Horsham, Pennsylvania, USA (RP)
    • ,
  • William Wechter

      Affiliations

    • Encore Pharmaceuticals, Loma Linda, California, USA (WW)
    • ,
  • Robert J Padley

      Affiliations

    • Abbott Pharmaceuticals, Abbott Park, Illinois, USA (RJP)

References 

  1. Gao X, Grignon DJ, Chbihi T, et al.  Elevated 12-lipoxygenase mRNA expression correlates with advanced stage and poor differentiation of human prostate cancer. Urology. 1995;46:227–237
  2. Ghosh J, Myers CE. Arachidonic acid stimulates prostate cancer cell growth (critical role of 5-lipoxygenase). Biochem Biophys Res Commun. 1997;235:418–423
  3. Ghosh J, Myers CE. Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc Natl Acad Sci USA. 1998;95:13182–13187
  4. Bonewald LF, Flynn M, Qiao M, et al.  Mice lacking 5-lipoxygenase have increased cortical bone thickness. Adv Exp Med Biol. 1997;433:299–302
  5. Franchi-Miller C, Saffar JL. The 5-lipoxygenase inhibitor BWA4C impairs osteoclastic resorption in a synchronized model of bone remodeling. Bone. 1995;17:185–191
  6. Stenke L, Reizenstein P, Lindgren JA. Leukotrienes and lipoxins—new potential performers in the regulation of human myelopoiesis. Leuk Res. 1994;18:727–732
  7. Chaudry AA, Wahle KW, McClinton S, et al.  Arachidonic acid metabolism in benign and malignant prostatic tissue in vitro (effects of fatty acids and cyclooxygenase inhibitors). Int J Cancer. 1994;57:176–180
  8. Gupta S, Srivastava M, Ahmad N, et al.  Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate. 2000;42:73–78
  9. Sawaoka H, Tsuji S, Tsujii M, et al.  Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab Invest. 1999;79:1469–1477
  10. Tsujii M, Kawano S, Tsuji S, et al.  Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998;93:705–716
  11. Liu XH, Yao S, Kirschenbaum A, et al.  NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res. 1998;58:4245–4249
  12. Rhind SG, Gannon GA, Suzui M, et al.  Indomethacin inhibits circulating PGE2 and reverses postexercise suppression of natural killer cell activity. Am J Physiol. 1999;276:R1496–R1505
  13. Reddy BS, Hirose Y, Lubet R, et al.  Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res. 2000;60:293–297
  14. Kawamori T, Rao CV, Seibert K, et al.  Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 1998;58:409–412
  15. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci. 2000;30:3–21
  16. Masferrer JL, Lehy KM, Koki AT. Role of cyclooxygenases in angiogenesis. Curr Med Chem. 2000;7:1163–1170
  17. Burke C, van Stolk R, Arber N, et al: Exislund prevents adenoma formation in familial adenomatous polyposis (FAP) [abstract 3604]. Gastroenterology 118(4, suppl 2): A657, 2000.
  18. Burke C, Arber N, Phillips R, et al.  Exislund continues to prevent colonic adenoma formation in familial adenomatous polyposis (FAP) patients treated for 18 months. Gastroenterology. 2000;118(4, suppl 2):A657;[abstract 3605]
  19. Stoner GD, Budd GT, Ganapathi R, et al: Sulindac sulfone induced regression of rectal polyps in patients with familial adenomatous polyposis. Colon Cancer Prevention—AICR. Plenum Press, 1999, pp 45–53.
  20. Thompson HJ, Briggs S, Paranka NS, et al.  Sulfone metabolite of sulindac inhibits mammary carcinogenesis. J Natl Cancer Inst. 1995;85:1259–1261
  21. Piazza GA, Pamukcu R, Ahnen DJ, et al.  Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res. 1997;57:2909–2915
  22. Thompson HJ, Ahnen DJ, Pamukcu R, et al.  Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer Res. 1997;57:267–271
  23. Malkinson AM, Koshi KM, Dwyer-Nield LD, et al.  Inhibition of NNK-induced mouse lung tumor formation by FGN-1 (sulindac sulfone). Carcinogenesis. 1998;8:1353–1364
  24. Piazza GA, Pamukcu R, Thompson WJ, et al.  Inhibition of urinary bladder tumorigenesis in rats by exisulind (Aptosyn). J Urol. 2000;163(suppl 4):122
  25. Lim JT, Piazza GA, Han EK, et al.  Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines. Biochem Pharmacol. 1999;58:1097–1107
  26. Goluboff ET, Shabsigh A, Saidi JA, et al.  Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis. Urology. 1999;53:440–445
  27. Pound CR, Partin AW, Eisenberger MA, et al.  Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591–1597
  28. McCracken JD, Wechter WJ, Liu Y, et al.  Antiproliferative effects of the enantiomers of flurbiprofen. J Clin Pharmacol. 1996;36:540–545
  29. Wechter WJ, Kantoci D, Murray ED, et al.  R-flurbiprofen chemoprevention and treatment of intestinal adenomas in the APC(Min)/+ mouse model (implications for prophylaxis and treatment of colon cancer). Cancer Res. 1997;57:4316–4324
  30. Wechter WJ, Murray ED, Kantoci D, et al.  Treatment and survival study in the C57BL/6J-APC(Min)/+(Min) mouse with R-flurbiprofen. Life Sci. 2000;66:745–753
  31. Loughman BE, Keegan P. Early clinical trials of chemopreventive agents and biologics (designs, populations, and endpoints). Urology. 2001;57(Suppl 4A):216–219

PII: S0090-4295(00)00945-6

Urology
Volume 57, Issue 4, Supplement 1 , Pages 73-76 , April 2001

Article Tools